Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.
Nan Bi, Jianyang Wang, Wei Jiang et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase III ADVANCE trial evaluated a chemotherapy-free regimen of aumolertinib combined with radiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer. The study found that the experimental arm had a significantly longer progression-free survival (PFS) of 34.0 months compared to 7.4 months in the control arm (HR 0.15; P < 0.001).
Key findings
- The experimental arm achieved a median PFS of 34.0 months compared to 7.4 months in the control arm (HR 0.15; P < 0.001).
- Median overall survival was not reached in the experimental arm versus 30.5 months in the control arm (HR = 0.32; P = 0.09).
- Neutropenia and nausea were more common in the control arm, while quality of life favored the experimental arm.
- Real-world validation showed similar outcomes for TKIs + RT and TKIs + cCRT, both superior to cCRT (P < 0.001).
Why it matters
This study introduces a novel treatment approach for unresectable stage III EGFR-mutant NSCLC, potentially improving patient outcomes by avoiding chemotherapy while still achieving significant progression-free survival benefits.
What to keep in mind
The trial was terminated early due to slow accrual and loss of equipoise, which may affect the robustness of the findings.